Search company, investor...
OMass Therapeutics company logo

OMass Therapeutics

Founded Year



Series B | Alive

Total Raised


Last Raised

$100M | 1 yr ago

About OMass Therapeutics

OMass Therapeutics is a biotechnology company that is focused on using structural mass spectrometry to discover medicines. It uses its suite of technologies based on high-resolution mass spectrometry to study intact protein assemblies. OMass Therapeutics was founded in 2016 and is based in Oxford, England.

Headquarters Location

The Schrödinger Building Heatley Road, The Oxford Science Park

Oxford, England, OX4 4GE,

United Kingdom

+44 (0) 1865 548350

Compete with OMass Therapeutics?

Ensure that your company and products are accurately represented on our platform.

OMass Therapeutics's Products & Differentiators


    GPCR targeting orphan endocrine disorders

Expert Collections containing OMass Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OMass Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest OMass Therapeutics News

The women founders contributing to Oxford’s spinout success

Mar 8, 2023

More spinout companies are created by the University of Oxford than any other UK University and an increasing number of their founders and senior leaders are women. One such company is Omass Therapeutics which spun out of the Department for Chemistry in 2016. It utilises high-resolution mass spectrometry to drive drug discovery for immunology and genetic disease and last year received $100million investment to advance its technology. The company has two female founders, a female CEO and a female Vice President. The company also has a gender balanced board. We made a conscious decision to ensure that women are properly represented in our senior leadership team and on our board. Diversity means better discussion, better decisions and ultimately better results. I hope that by seeing this representation in companies like Omass, more women will be encouraged to pursue similar roles in fields, such as artificial intelligence and biotech, where currently only 1 in 5 professionals are women. Professor Dame Carol Robinson, founder, OMass Therapeutics Nucle ome Therapeutics  is another female-led company which spun out of the University in 2019. This fast-emerging biopharma uses cutting-edge 3D genome technologies and machine learning to find genetic drivers of disease, and design drugs against them. Last year, the company raised £37.5 million to continue to decode the genetics hidden in the ‘dark’ regions of the human genome and advance its autoimmune disease programmes. Dr Danuta Jeziorska , founder and CEO of Nucleome Therapeutics, said: ‘I am thrilled to see more women pursuing careers in the biotech industry. During my time at Oxford, I leveraged support from various entrepreneurial initiatives, Saïd Business School, and directed the Innovation Forum and Oxfordshire Women in Tech network. Having access to the right guidance and mentorship is crucial to fostering a diverse business community where women are empowered with the confidence to realise the fullest extent of their ambitions.’ Yet recent research from the Centre for Diversity Policy Research and Practice at Oxford Brookes University shows that only 18% of spinout companies have a woman founder and this is reflective of the global picture of women across business and industry where fewer than a quarter hold senior leadership positions. Through its IDEA programme , the University of Oxford is committed to tackling some of the key challenges and inequalities faced by groups who are currently vastly underrepresented in enterprise and industry across the world. Its first initiatives are aimed at empowering, inspiring, connecting and upskilling more women leaders, business founders and pioneers. Professor  Kylie Vincent is co-founder of HydRegen , an Oxford spinout developing bio-based technologies for cleaner, safer and more efficient chemical manufacturing. She is also the University’s  Champion for Women in Entrepreneurship , and works closely with IDEA. Professor Kylie Vincent She said: ‘There are more female founders and entrepreneurs than ever before. This is great news but numbers remain relatively low and more must be done to balance gender representation. The IDEA programme offers brilliant opportunities for students and researchers including board experience, mentoring, an entrepreneurial skills programme, events and networking. With equality some way off, it’s so important that we support and empower women to achieve their goals and become the founders or the future.’ It has also been found that, on average, companies with female founders find it harder to raise investment in funding rounds. According to research by Enterprising Oxford, in 2020 less than 2% of European tech investment capital went to female founders. Oxford University Innovation (OUI), is the research commercialisation arm of the University, supporting innovation, entrepreneurial and consulting activities across all University Divisions. Adam Workman, Head of Investment & New Ventures at OUI said, ‘We’re exploring new ways to encourage more women to consider founding a spinout and increase diversity in our existing pipeline of spinout management teams. We need to inspire, train and support women to embark and continue the founder journey. It will take time and perseverance to get to where we want to be.’ Oxford Science Enterprises , the independent investment company which founds, funds and builds companies from the University of Oxford, is also committed to increasing gender equality both internally and across its portfolio. Chief Talent Officer Sarah Shackelton , who has over 20 years of experience building the boards and senior leadership teams of innovative growth companies, said: ‘OSE is strongly committed to gender equality and to a supportive, diverse working environment across our portfolio companies. We have some inspiring women in senior leadership roles within OSE, including our senior life sciences partner Katya Smirnyagina , and more than 25 female founders across our portfolio companies in Life Sciences, Health Tech and Deep Tech. Gender equality is a constant focus in all of our talent recruitment efforts and we strive for equal opportunities to achieve the best outcomes.’

OMass Therapeutics Frequently Asked Questions (FAQ)

  • When was OMass Therapeutics founded?

    OMass Therapeutics was founded in 2016.

  • Where is OMass Therapeutics's headquarters?

    OMass Therapeutics's headquarters is located at The Schrödinger Building, Oxford.

  • What is OMass Therapeutics's latest funding round?

    OMass Therapeutics's latest funding round is Series B.

  • How much did OMass Therapeutics raise?

    OMass Therapeutics raised a total of $153.83M.

  • Who are the investors of OMass Therapeutics?

    Investors of OMass Therapeutics include Syncona Partners, Oxford Science Enterprises, University of Oxford, Google Ventures, Sanofi Ventures and 3 more.

  • Who are OMass Therapeutics's competitors?

    Competitors of OMass Therapeutics include Red Horse Oil and 1 more.

  • What products does OMass Therapeutics offer?

    OMass Therapeutics's products include MC2 and 4 more.

Compare OMass Therapeutics to Competitors

Berar Finance

Berar Finance operates as a non-banking finance company based in Maharashtra, India.

NVI Solutions

NVI Solutions develops a software tool, Cyclops, that analyzes a video stream of employees. It monitors their compliance with safety regulations and the compliance of operations with production technology.

Diversity in Blockchain Logo
Diversity in Blockchain

Diversity in Blockchain Inc. (DiB) is a nonprofit organization that aims to help create opportunities in the blockchain industry.

Domain Therapeutics Logo
Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs). Domain Therapeutics discovers allosteric modulators by exploiting its DTect-All technology. The company's pipeline is composed of new chemical entities, ranging from hits to optimized leads for significant indications such as schizophrenia, Parkinson's disease, and diabetes. It is based in Illkirch-Strasbourg, France, and was founded in 2001.

Verseau Therapeutics

Verseau develops a class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. With its all-human translational platform, the company identifies targets and develop therapies that shift macrophages between immune activators and silencers in disease.

ENB Therapeutics

ENB Therapeutics develops therapies to break the drug resistance that occurs in over 50% of cancer patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.